1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis

Journal of Neurology Neurosurgery and Psychiatry

Volumn 63, Issue 6, 1997, Pages 736-742

  Davie, C A ^a   Barker, G J ^a   Thompson, A J ^a   Tofts, P S ^a   McDonald, W I ^a   Miller, D H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Disability; Multiple sclerosis; N acetyl aspartate

Indexed keywords

N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; HUMAN; HYPOTHESIS; MULTIPLE SCLEROSIS; NERVE FIBER; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RELAPSE; REMISSION; WHITE MATTER; ADOLESCENT; BRAIN; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RECURRENT DISEASE;

ADOLESCENT; ADULT; BRAIN; CHRONIC DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SCLEROSIS; RECURRENCE; REMISSION, SPONTANEOUS;

EID: 0030609055     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.63.6.736     Document Type: Article

References (39)

1. Thompson AJ, Miller D, Youl B, MacManus D, Moore S, Kingsley D, et al. Serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-3.
2. Thompson AJ, Kermode AG, Wicks D, MacManus. D, Kendall BE, Kingsley DPE, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62.
3. McAlpine D. The benign form of multiple sclerosis. A study based on 241 cases within three years of onset and followed up until the tenth year or more of the disease. Brain 1961; 84:186-203.
4. Kidd D, Thompson AJ, Kendall BE, Miller DH, McDonald WI. The benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. J Neurol Neurosurg Psychiatry 1994;57:1070-2.
5. Li DKB, Mayo J, Fache S, Robertson W, Kastrukoff LF, Oger J, et al. Lack of correlation between clinical manifestations and lesions of MS seen by NMR [abstract]. Neurology 1984;34(suppl 1):S136.
6. Thompson AJ, Kermode AG, MacManus DG, Kendall BE, Kingsley DPE, Moseley IF, et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ 1990;300:631-1.
7. 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989; 13:23-31.
8. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993;13: 981-9.
9. Davie CA, Wenning GK, Barker GJ, Tofts PS, Quinn N, Marsden CD, et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 1995;37:204-10.
10. Gideon P, Henriksen O, Sperling B, Permille C, Skyhøj Olsen T, Jørgensen HS, et al. Early time course of N acetylaspartate, creatine and phosphocreatine, and compounds containing choline in the brain after acute stroke. A proton magnetic resonance spectroscopy study. Stroke 1992;23: 1566-72.
11. 31P magnetic resonance spectroscopy of brain degenerative cerebral disorders. Ann Neurol 1992;31:202-11.
12. Chong WK, Sweeney B, Wilkinson ID, Paley M, Hall-Craggs MA, Kendall BE, et al. Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic and MR imaging findings. Radiology 1993;188:119-24.
13. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
14. Frahm J, Merboldt KD, Hanicke W. Localised proton spectroscopy using stimulated echoes. J Magn Reson 1987;72: 502-8.
15. Frahm J, Michaelis T, Bruhn H, Gyngell ML, Merboldt KD, Hänicke W. Improvements in localised proton NMR spectroscopy of human brain, water suppression, short echo times and 1ml resolution. J Magn Reson 1990;290: 464-73.
16. 1H-MRS using water as an internal standard. Magn Reson Imaging 1993;11:107-18.
17. Olanow CW. Magnetic resonance imaging in parkinsonism. Neurol Clin 1992;10:405-20.
18. Grimaud J, Millar J, Thorpe JW, Moseley IF, McDonald WI, Miller DH. Signal intensity on MRI of basal ganglia in multiple sclerosis. J Neurol Neurosurg Psychiatry 1995;59: 306-8.
19. Norton WT, Poduslo SE, Suzuki K. Subacute sclerosing leukoencephalitis. II. Chemical studies including abnormal myelin and an abnormal ganglioside pattern. J Neuropathol Exp Neurol 1966;25:582-97.
20. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hänicke W, Sauter R. Localised proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites. Magn Reson Med 1989;11:47-63.
21. 1H spectrum of rat brain by two-dimensional shift correlated and J-resolved NMR spectroscopy. Magn Reson Med 1991; 17:285-303.
22. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990;14:154-9.
23. Miller DH, Austin SJ, Connelly A, Youl BD, Gadian DG, McDonald WI. Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis [letter]. Lancet 1991;337:58-9.
24. Husted CA, Goodin S, Hugg JW, Maudsley A, Tsuruda JS, de Brie SH. Biochemical alterations in multiple sclerosis lesions and normal appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 1994; 36:157-65.
25. Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Harding AE, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995;118;1583-92.
26. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerised data processing of 349 patients. Brain 1980;103:281-300.
27. Thompson AJ, Hutchinson M, Brazil J, Martin EA. A clinical and laboratory study of multiple sclerosis. Q J Med 1986;58:69-80.
28. Kidd D, Thorpe JW, Thompson AJ, Kendall BE, Moseley IF, MacMannus DG, et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993;43:2632-7.
29. Arnold DL, Matthews PM, Francis GS, O'Connor, Antel J. Proton magnetic resonance spectroscopic imaging for metabolic characterisation of demyelinating plaques. Ann Neurol 1992;31:235-41.
30. Phadke JG, Best PV. Atypical and clinically silent multiple sclerosis: a report of 12 cases discovered unexpectedly at necropsy. J Neurol Neurosurg Psychiatry 1983;46:414-20.
31. Rao SM, Leo GJ, Haughton VM, St Aubin-Faubert P, Bernardin L. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. Neurology 1989;39:161-6.
32. Feinstein A, Ron M, Thompson AJ. A serial study of psychometric and MRI changes in multiple sclerosis. Brain 1993;116:569-602.
33. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995; 38:901-9.
34. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58.
35. Allen IV. Pathology of multiple sclerosis. In: Matthews WB, Compston A, Allen IV, Martyn CM, eds. McAlpine's multiple sclerosis. 2nd ed. Edinburgh: Churchill Livingstone, 1991:341-78.
36. Davies SEC, Newcombe J, Williams SR, McDonald WI, Clark JB. High resolution proton NMR spectroscopy of multiple sclerosis lesions. J Neurochem 1995;64:742-8.
37. IFBN Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
38. Comment in: Neurology 1993;43:641-3.
39. Paty DW, Oger JJF, Kastrukoff LF, Hashimoto SA, Hooge JP, Eisen AA, et al. MRI in the diagnosis of MS: a prospective study and comparison of clinical evaluation, evoked potentials, oligoclonal banding and CT. Neurology 1988;38: 180-4.